Medtronic’s diabetes spin-off gets a name, kicking off ‘new and exciting chapter’

Michael Walter | June 13, 2025 | Cardiovascular Business | Heart Health

Medtronic has announced that MiniMed will be the name of its planned diabetes spin-off. MiniMed was also the original name of the medtech giant’s diabetes business before it was acquired by Medtronic in 2001.

The news comes just weeks after Medtronic announced its plans to turn its California-based diabetes business into a separate publicly traded company. The standalone entity includes a team of more than 8,000 employees. It is expected to launch within the next 18 months after a series of capital market transactions and, preferably, an initial public offering followed by a split-off transaction.

“This marks a significant milestone in driving both Medtronic and the diabetes business to achieve lasting value for Medtronic, our shareholders, customers and patients,” Geoff Martha, chairman and CEO of Medtronic, said at the time. “Active portfolio management is an important lever to delivering on our ongoing growth and success, and this decision shifts the Medtronic portfolio to have intense focus on our highest margin growth drivers where we have our strongest core competencies.”

Que Dallara, the current president of Medtronic’s diabetes business, is set to be MiniMed’s CEO once it officially launches.

“Our journey began in 1983, when visionary entrepreneur Alfred E. Mann founded MiniMed and revolutionized diabetes care with many first-of-its-kind innovations that pushed the boundaries of care and helped simplify life with diabetes for countless people around the world,” Dallara said in a new statement. “We're thrilled to honor this rich 40-year legacy with a name that carries deep meaning and trust. As we step forward into this new and exciting chapter, we'll focus relentlessly on fulfilling our mission to make diabetes more predictable so everyone can embrace life to the fullest.”

Medtronic to spin off its diabetes business

Medtronic and Abbott make progress on interoperable diabetes tech—is FDA clearance next?

Wearable heart device company to go public, raise up to $155M

HeartBeam raising $10M for FDA-cleared health tech with public offering

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations.

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.